Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Purpose
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Condition
- Alzheimers Disease
Eligibility
- Eligible Ages
- Between 50 Years and 90 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.
Exclusion Criteria
- Dependency in basic activities of daily living (bADLs) due to cognitive impairment - Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted) - Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD - History of severe, clinically significant central nervous system trauma - Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Screening
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Other Screening Arm |
Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT). |
|
Recruiting Locations
Phoenix, Arizona 85006
Sun City, Arizona 85351
Imperial, California 92251
Inglewood, California 90301
Irvine, California 92614
Long Beach, California 90804
Oakland, California 94609
Riverside, California 92506
Santa Ana, California 92705
Sherman Oaks, California 91403
New Haven, Connecticut 06510
Atlantis, Florida 33462
Clermont, Florida 34711
Lady Lake, Florida 32159
Maitland, Florida 32751
Miami, Florida 33133
Ocala, Florida 34470
Orlando, Florida 32803
Orlando, Florida 32832
Stuart, Florida 34997
Tampa, Florida 34654
The Villages, Florida 32162
Wellington, Florida 33414
Winter Park, Florida 32789
Atlanta, Georgia 30303
Columbus, Georgia 31904
Decatur, Georgia 30030
Decatur, Georgia 30030
Gainesville, Georgia 30501
Honolulu, Hawaii 96817
Chicago, Illinois 60611
Chicago, Illinois 60640
Marrero, Louisiana 70072
Boston, Massachusetts 02116
Newton, Massachusetts 02459
Watertown, Massachusetts 02472
Farmington Hills, Michigan 48334
St Louis, Missouri 63110
Ridgewood, New Jersey 07450
Springfield, New Jersey 07081
Albuquerque, New Mexico 87109
Laurelton, New York 11413-2016
New York, New York 10021
New York, New York 10029
Rochester, New York 14620
The Bronx, New York 10461
Greensboro, North Carolina 27410
Columbus, Ohio 43221
Portland, Oregon 97210
Plymouth Meeting, Pennsylvania 19462
Providence, Rhode Island 02906
Charleston, South Carolina 29403
Summerville, South Carolina 29485
Knoxville, Tennessee 37909
Nashville, Tennessee 37204
Beaumont, Texas 77702
Brownsville, Texas 78520
Dallas, Texas 75216
Dallas, Texas 75231
Edinburg, Texas 78539
Fort Worth, Texas 76104
Houston, Texas 77030
Katy, Texas 77450
Rio Grande City, Texas 78582
Arlington, Virginia 22205
Fairfax, Virginia 22031
Richmond, Virginia 23294
San Juan, Puerto Rico 00935
More Details
- NCT ID
- NCT07177352
- Status
- Recruiting
- Sponsor
- Hoffmann-La Roche
Study Contact
Reference Study ID Number: WP45722 https://forpatients.roche.com/888-662-6728 (U.S. and Canada)
global-roche-genentech-trials@gene.com